RS Research
Istanbul
About RS Research
RS Research is a clinical-stage biotechnology start-up developing novel smart nanomedicines with superior therapeutic index. The company has discovered a novel drug delivery platform which empowers its current development programs in various preclinical and clinical stages for targeted therapies. The proprietary drug delivery platform Sagitta® allows designing targeted drug candidates for different indications, which yields into development of RS Research's current portfolio as well as an outstanding co-development potential. RS Research has a GMP-certified production facility for clinical development and has been successfully conducting co-development projects with its international partners. The company's lead candidate RS-0139 is currently studied under the clinical Phase I in oncology patients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $14.4M
- Funding stage: Early Stage Venture
- Last round: Grant (Mar 2024)
- Website: rsresearch.net
- Phone: +90 530 760 67 62
Industries & Categories
Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/rs-research-114096 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.